TY - JOUR
T1 - Outcomes From the Multicenter Italian Registry on Primary Endovascular Treatment of Aortoiliac Occlusive Disease
AU - Piffaretti, Gabriele
AU - Fargion, Aaron Thomas
AU - Dorigo, Walter
AU - Pulli, Raffaele
AU - Gattuso, Andrea
AU - Bush, Ruth L.
AU - Pratesi, Carlo
AU - Fontana, Federico
AU - Piacentino, Filippo
AU - Castelli, Patrizio
AU - Speziali, Sara
AU - Angiletta, Domenico
AU - Marinazzo, Davide
AU - Zacà, Sergio
AU - Grego, Franco
AU - Antonello, Michele
AU - Piazza, Michele
AU - Squizzato, Francesco
AU - Bellosta, Raffaello
AU - Pegorer, Matteo
AU - Ippoliti, Arnaldo
AU - Pratesi, Giovanni
AU - Citoni, Gianluca
AU - Benedetto, Filippo
AU - Pipitò, Narayana
AU - Derone, Graziana
AU - Ferri, Michelangelo
AU - Cumino, Andrea
AU - Suita, Roberta
AU - Gargiulo, Mauro
AU - Mascoli, Chiara
AU - Sonetto, Alessia
AU - Bracale, Umberto M.
AU - Turchino, Davide
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose: To report the results of endovascular treatment of iliac and complex aortoiliac occlusive disease (AIOD) in a multicenter Italian registry. Materials and Methods: A retrospective, multicenter, observational cohort study analyzed 713 patients (mean age 68±10 years; 539 men) with isolated iliac and complex aortoiliac lesions treated with primary stenting between January 2015 and December 2017. Indications for treatment were claudication in 406 (57%) patients and critical limb ischemia in 307 (43%). According to the TransAtlantic Inter-Society Consensus II (TASC) classification, the lesions were categorized as type A (104, 15%), type B (171, 24%), type C (170, 24%), and type D (268, 37%). Early ('30 days) endpoints included mortality, thrombosis, and major complications. Late major outcomes were primary and secondary patency and freedom from reintervention as estimated by Kaplan-Meier analysis; estimates are given with the 95% confidence intervals (CIs). Associations between baseline variables and primary patency were sought with multivariate analysis; the results are presented as the hazard ratio (HR) and 95% CI. Results: Technical success was achieved in 708 (99%) lesions; in-hospital mortality was 0.6% (n=4). The median follow-up was 11 months (range 0–42). The estimated primary patency rate was 96% (95% CI 94% to 97%) at 1 year and 94% (95% CI 91% to 96%) at 2 years. The estimated secondary patency was 99% (95% CI 97% to 99%) at 1 year and 98% (95% CI 95% to 99%) at 2 years. The estimated freedom from reintervention was 98% (95% CI 96% to 99%) at 1 year and 97% (95% CI 94% to 98.5%) at 2 years. Cox regression analysis demonstrated that the application of a covered stent was associated with an increased need for reintervention (HR 1.4, 95% CI 1.10 to 1.74, p=0.005). Chronic obstructive pulmonary disease was associated with decreased primary patency (HR 3.7, 95% CI 1.25 to 10.8, p=0.018). Conclusion: Endovascular intervention with primary stent placement for aortoiliac occlusive disease achieved satisfactory 2-year patency regardless of the complexity of the lesion. Almost all TASC lesions should be considered for primary endovascular intervention if suitable.
AB - Purpose: To report the results of endovascular treatment of iliac and complex aortoiliac occlusive disease (AIOD) in a multicenter Italian registry. Materials and Methods: A retrospective, multicenter, observational cohort study analyzed 713 patients (mean age 68±10 years; 539 men) with isolated iliac and complex aortoiliac lesions treated with primary stenting between January 2015 and December 2017. Indications for treatment were claudication in 406 (57%) patients and critical limb ischemia in 307 (43%). According to the TransAtlantic Inter-Society Consensus II (TASC) classification, the lesions were categorized as type A (104, 15%), type B (171, 24%), type C (170, 24%), and type D (268, 37%). Early ('30 days) endpoints included mortality, thrombosis, and major complications. Late major outcomes were primary and secondary patency and freedom from reintervention as estimated by Kaplan-Meier analysis; estimates are given with the 95% confidence intervals (CIs). Associations between baseline variables and primary patency were sought with multivariate analysis; the results are presented as the hazard ratio (HR) and 95% CI. Results: Technical success was achieved in 708 (99%) lesions; in-hospital mortality was 0.6% (n=4). The median follow-up was 11 months (range 0–42). The estimated primary patency rate was 96% (95% CI 94% to 97%) at 1 year and 94% (95% CI 91% to 96%) at 2 years. The estimated secondary patency was 99% (95% CI 97% to 99%) at 1 year and 98% (95% CI 95% to 99%) at 2 years. The estimated freedom from reintervention was 98% (95% CI 96% to 99%) at 1 year and 97% (95% CI 94% to 98.5%) at 2 years. Cox regression analysis demonstrated that the application of a covered stent was associated with an increased need for reintervention (HR 1.4, 95% CI 1.10 to 1.74, p=0.005). Chronic obstructive pulmonary disease was associated with decreased primary patency (HR 3.7, 95% CI 1.25 to 10.8, p=0.018). Conclusion: Endovascular intervention with primary stent placement for aortoiliac occlusive disease achieved satisfactory 2-year patency regardless of the complexity of the lesion. Almost all TASC lesions should be considered for primary endovascular intervention if suitable.
KW - aortoiliac occlusive disease
KW - covered stent
KW - iliac artery
KW - kissing stent
KW - occlusion
KW - primary patency
KW - reintervention
KW - stenosis
KW - stent
KW - TASC C and D lesions
UR - https://www.scopus.com/pages/publications/85070410346
UR - https://www.scopus.com/pages/publications/85070410346#tab=citedBy
U2 - 10.1177/1526602819863081
DO - 10.1177/1526602819863081
M3 - Article
C2 - 31331235
AN - SCOPUS:85070410346
SN - 1526-6028
VL - 26
SP - 623
EP - 632
JO - Journal of Endovascular Therapy
JF - Journal of Endovascular Therapy
IS - 5
ER -